Abstract: Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.
Type:
Grant
Filed:
March 21, 2001
Date of Patent:
January 11, 2005
Assignee:
Allergan, Inc.
Inventors:
Ken Chow, Daniel W. Gil, James A. Burke, Dale A. Harcourt, Michael E. Garst, Larry A. Wheeler, Stephen A. Munk, Dario G. Gomez, Todd M. Heidelbaugh
Abstract: Methods for treating endocrine disorders and for inhibiting gametogenesis by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
Abstract: According to the invention there is provided a compound the formula I;
wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I,
wherein Y is (CH2)x; Z is selected from the group consisting of
x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein t
Type:
Grant
Filed:
August 5, 2002
Date of Patent:
November 16, 2004
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Achim H-P Krauss, David F. Woodward
Abstract: The present invention provides a compound represented by the general formula I;
wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.
Type:
Grant
Filed:
January 26, 2004
Date of Patent:
November 2, 2004
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Thang D. Dinh, Robert M. Burk
Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein hatched lines represent the &agr; configuration, a triangle represents the &bgr; configuration, a wavy line represents the &agr; configuration or the &bgr; configuration and a dotted line represents the presence or absence of a double bond;
A and B are independently selected from the group consisting of O, S and CH2;
provided that at least one of A or B is S;
D represents a covalent bond or CH2, O, S or NH;
X is CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R SONR2 or
Y is O, OH, OCOR2, halogen or cyano;
Z is CH2 or a covalent bond;
R is H or R2;
R1 is H, R2, phenyl, or COR2;
R2 is C1-C5 lower alkyl or alkenyl and R3 is benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents may
Type:
Grant
Filed:
January 16, 2003
Date of Patent:
July 27, 2004
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Mari F. Posner
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
July 20, 2004
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein X, Y, Z, D and R3 are as defined in the specification.
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
Type:
Grant
Filed:
March 13, 2003
Date of Patent:
June 8, 2004
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
Abstract: Compounds of Formula 1:
wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.
Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein X, Y, Z, D and R3 are as defined in the specification.
Type:
Grant
Filed:
June 2, 2003
Date of Patent:
May 11, 2004
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Thang D. Dinh, Robert M. Burk
Abstract: The present invention provides a compound represented by the general formula I;
wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.
Type:
Grant
Filed:
June 2, 2003
Date of Patent:
May 11, 2004
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Thang D. Dinh, Robert M. Burk
Abstract: The present invention relates to a method of treating psoriasis and/or photo damage in humans with tazarotene in a topical composition from 0.01 to 15% by weight tazarotene, and an alpha or beta-hydroxy acid in a topical composition comprising from 1 to 25% by weight alpha or beta-hydroxy acid. Furthermore, the present invention relates to treating or preventing psoriasis and/or photo damage by topically applying to the skin of a human, tazarotene, such as a gel comprising 0.01% to 0.1%, tazarotene by weight, and an alpha hydroxy acid, such as a cream, comprising 5% to 20% alpha hydroxy acid, e.g. glycolic acid, by weight.
Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.
Abstract: The present invention provides novel compounds represented by the general formula I.
wherein m, n, X, Y, Z, R, R1 and R2 are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF2&agr; antagonists, useful in pharmaceutical compositions for treating PGF2&agr;-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.
Abstract: Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
March 30, 2004
Assignee:
Allergan, Inc.
Inventors:
David F. Woodward, Licheng Shi, Achim H-P Krauss, Clayton S. Spada, Sheila Mac Neil, Linda C. Smith-Thomas
Abstract: Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Type:
Grant
Filed:
February 11, 2003
Date of Patent:
March 30, 2004
Assignee:
Allergan, Inc.
Inventors:
Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Roshantha A. Chandraratna
Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives.
Type:
Grant
Filed:
October 29, 2002
Date of Patent:
March 23, 2004
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Mari F. Posner